Last reviewed · How we verify
Risperidone, Haloperidol
Risperidone and haloperidol are antipsychotic medications that block dopamine and serotonin receptors in the brain to reduce psychotic symptoms.
Risperidone and haloperidol are antipsychotic medications that block dopamine and serotonin receptors in the brain to reduce psychotic symptoms. Used for Schizophrenia, Bipolar disorder (acute mania and maintenance), Irritability associated with autism spectrum disorder.
At a glance
| Generic name | Risperidone, Haloperidol |
|---|---|
| Sponsor | Ludwig-Maximilians - University of Munich |
| Drug class | Antipsychotic |
| Target | Dopamine D2 receptor, Serotonin 5-HT2A receptor |
| Modality | Small molecule |
| Therapeutic area | Psychiatry/Neurology |
| Phase | FDA-approved |
Mechanism of action
Risperidone is an atypical antipsychotic that antagonizes dopamine D2 receptors and serotonin 5-HT2A receptors, while haloperidol is a typical antipsychotic that primarily blocks D2 receptors. Both reduce dopaminergic and serotonergic neurotransmission in key brain regions involved in psychosis, thereby alleviating hallucinations, delusions, and disorganized thinking.
Approved indications
- Schizophrenia
- Bipolar disorder (acute mania and maintenance)
- Irritability associated with autism spectrum disorder
- Acute agitation
Common side effects
- Extrapyramidal symptoms (tremor, rigidity, akathisia)
- Tardive dyskinesia
- Weight gain
- Hyperprolactinemia
- Sedation
- Orthostatic hypotension
- QT prolongation
Key clinical trials
- Maternal And Infant Antipsychotic Study
- A Study to Assess Stroke Risk Among Users of Typical Versus Atypical Antipsychotics Stratified by Broad Age Group
- A Study to Compare Disease Progression and Modification Following Treatment With Paliperidone Palmitate Long-Acting Injection or Oral Antipsychotics in Participant's With Recent-onset Schizophrenia or Schizophreniform (PHASE3)
- A Study for Schizophrenia Relapse Prediction
- Study to Compare Clozapine vs Treatment as Usual in People With Intellectual Disability & Treatment-resistant Psychosis (PHASE2)
- Longitudinal Comparative Effectiveness of Bipolar Disorder Therapies
- Correlation Between Cognitive Function and Relapse of Schizophrenia Regarding Dose Reduction (NA)
- Optimizing and Individualizing the Pharmacological Treatment of First-episode Schizophrenic Patients
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Risperidone, Haloperidol CI brief — competitive landscape report
- Risperidone, Haloperidol updates RSS · CI watch RSS
- Ludwig-Maximilians - University of Munich portfolio CI